French vaccines company Valneva SE is planning to list on the NASDAQ to fund Phase III studies of the much-needed vaccine for Lyme disease.
The company had a dual listing on the Vienna Stock Exchange and the EuroNext Paris, a legacy from Valneva’s formation...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
